Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 3/20 | 0.38 |
| ▸ | SKP1 | P63208 | 3/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3755022 | 0.85 | CKS1B (0.37) | CKS1BSKP1SKP2GPR119USP30 | |
| SCHEMBL3766118 | 0.83 | GPR119 (0.35) | CKS1BSKP1SKP2GPR119USP30 | |
| SCHEMBL3756655 | 0.75 | HTT (0.48) | MEN1KMT2APOLBLMNA | |
| SCHEMBL3751948 | 0.74 | SMN1; SMN2 (0.47) | TP53MEN1KMT2A | |
| SCHEMBL3758808 | 0.73 | TSHR (0.50) | MEN1KMT2APOLBLMNA | |
| SCHEMBL3763222 | 0.72 | CKS1B (0.35) | CKS1BSKP1SKP2GPR119USP30 | |
| SCHEMBL3758917 | 0.72 | CNR1 (0.46) | MEN1KMT2APOLBLMNA | |
| SCHEMBL3765086 | 0.72 | TSHR (0.49) | MEN1KMT2A | |
| SCHEMBL3765112 | 0.71 | CKS1B (0.41) | CKS1BSKP1SKP2USP30HPGDS | |
| SCHEMBL3760094 | 0.69 | AXL (0.45) | MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2029570-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | CKS1B 622/4885SKP1 433/4885SKP2 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.